Literature DB >> 34918288

Processing and Analysis of Ascites.

Hannah M Micek1, Molly J Carroll1, Lisa Barroilhet2,3, Pamela K Kreeger4,5.   

Abstract

The accumulation of peritoneal fluid, referred to as ascites, is common in ovarian cancer. This fluid is a complex mixture that may include cells as well as a diverse array of cytokines and growth factors. Here we describe a comprehensive method to process ascites to maximize data collection. The cellular fraction and fluid are first separated by centrifugation. The fluid can be frozen for later analysis of soluble factors or for use in in vitro experiments. The cellular fraction can be processed to analyze its composition or stored for future use.
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Aggregates; Ascites; Ovarian cancer

Mesh：

Substances：

Year:  2022        PMID： 34918288     DOI： 10.1007/978-1-0716-1956-8_5

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN： 1064-3745


  14 in total

1.  Alternatively-Activated Macrophages Upregulate Mesothelial Expression of P-Selectin to Enhance Adhesion of Ovarian Cancer Cells.

Authors:  Molly J Carroll; Kaitlin C Fogg; Harin A Patel; Harris B Krause; Anne-Sophie Mancha; Manish S Patankar; Paul S Weisman; Lisa Barroilhet; Pamela K Kreeger
Journal:  Cancer Res       Date:  2018-05-08       Impact factor: 12.701

2.  Impact of ascites volume on clinical outcomes in ovarian cancer: A cohort study.

Authors:  J Brian Szender; Tiffany Emmons; Sarah Belliotti; Danielle Dickson; Aalia Khan; Kayla Morrell; A N M Nazmul Khan; Kelly L Singel; Paul C Mayor; Kirsten B Moysich; Kunle Odunsi; Brahm H Segal; Kevin H Eng
Journal:  Gynecol Oncol       Date:  2017-06-16       Impact factor: 5.482

3.  Abrogation of taxol-induced G2-M arrest and apoptosis in human ovarian cancer cells grown as multicellular tumor spheroids.

Authors:  A Frankel; R Buckman; R S Kerbel
Journal:  Cancer Res       Date:  1997-06-15       Impact factor: 12.701

4.  Comparative Study of Multicellular Tumor Spheroid Formation Methods and Implications for Drug Screening.

Authors:  Maria F Gencoglu; Lauren E Barney; Christopher L Hall; Elizabeth A Brooks; Alyssa D Schwartz; Daniel C Corbett; Kelly R Stevens; Shelly R Peyton
Journal:  ACS Biomater Sci Eng       Date:  2017-03-13

5.  Formation of stable small cell number three-dimensional ovarian cancer spheroids using hanging drop arrays for preclinical drug sensitivity assays.

Authors:  Shreya Raghavan; Maria R Ward; Katelyn R Rowley; Rachel M Wold; Shuichi Takayama; Ronald J Buckanovich; Geeta Mehta
Journal:  Gynecol Oncol       Date:  2015-04-22       Impact factor: 5.482

6.  Transfection by human oncogenes: concomitant induction of tumorigenicity and tumor-associated membrane alterations.

Authors:  J G Collard; W P van Beek; J W Janssen; J F Schijven
Journal:  Int J Cancer       Date:  1985-02-15       Impact factor: 7.396

7.  Isolation and characterization of tumor cells from the ascites of ovarian cancer patients: molecular phenotype of chemoresistant ovarian tumors.

Authors:  Ardian Latifi; Rodney B Luwor; Maree Bilandzic; Simon Nazaretian; Kaye Stenvers; Jan Pyman; Hongjian Zhu; Erik W Thompson; Michael A Quinn; Jock K Findlay; Nuzhat Ahmed
Journal:  PLoS One       Date:  2012-10-08       Impact factor: 3.240

8.  Malignant ascites enhances migratory and invasive properties of ovarian cancer cells with membrane bound IL-6R in vitro.

Authors:  Soochi Kim; HyeRan Gwak; Hee Seung Kim; Boyun Kim; Danny N Dhanasekaran; Yong Sang Song
Journal:  Oncotarget       Date:  2016-12-13

9.  Multicellular detachment generates metastatic spheroids during intra-abdominal dissemination in epithelial ovarian cancer.

Authors:  Sara Al Habyan; Christina Kalos; Joseph Szymborski; Luke McCaffrey
Journal:  Oncogene       Date:  2018-05-23       Impact factor: 9.867

Review 10.  Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research.

Authors:  Nuzhat Ahmed; Kaye L Stenvers
Journal:  Front Oncol       Date:  2013-09-25       Impact factor: 6.244
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.